Core Viewpoint - The article discusses the recent surge in IPO activities on the Beijing Stock Exchange (北交所), highlighting the rapid pace of new stock listings and the strong market performance of newly listed companies, indicating a positive trend for investors and the market overall [3][4][6]. Group 1: IPO Activities - Three listing committee meetings and two new stock listings occurred within a week, with Aisheren (爱舍伦) debuting on January 21, 2026, and experiencing a significant first-day increase of 175.59%, closing at 44.04 yuan per share [3][4]. - Aisheren's IPO details include an issuance price of 15.98 yuan per share, a price-to-earnings ratio of 14.99, and total funds raised amounting to 270 million yuan [4]. - The upcoming listing of Guoliang New Materials (国亮新材) is set for January 22, 2026, contributing to a total of three new stocks listed in January [5]. Group 2: Market Performance - In 2025, the Beijing Stock Exchange had 26 new stocks listed, averaging about two per month, with some months seeing up to five listings [6]. - The average first-day increase for new stocks in 2025 was approximately 368%, with notable performers like Dapeng Industrial (大鹏工业) achieving a 1211.11% increase [6][8]. - The strong performance of new stocks has led to a significant market expectation for continued high returns, with no stocks experiencing a first-day drop in 2025 [6][8]. Group 3: Listing Review Acceleration - The listing review process on the Beijing Stock Exchange has accelerated, with six committee meetings held in January 2026 alone, indicating a trend of increased efficiency in the IPO process [7][8]. - Analysts note that the review process for specialized and innovative companies has become notably quicker, with some companies moving from application to approval in just a few months [8]. - The focus of the listing reviews appears to be on high-tech and advanced manufacturing sectors, reflecting a strategic support for these industries [8]. Group 4: Subscription and Frozen Capital - The subscription for new stocks has seen a significant increase, with frozen capital exceeding 800 billion yuan for several recent IPOs, indicating strong investor interest [9][12]. - Aisheren attracted 695,800 participants in its subscription, with a total frozen capital of 8789.21 million yuan [14]. - The upcoming IPOs of Nongda Technology (农大科技) and Meidel (美德乐) are expected to further increase the frozen capital, reflecting ongoing investor enthusiasm for new listings [16].

【中国上市地图重构： #苏州去年拿下A股IPO数量第一# ，#上海掀赴港上市热# 】 1月21日，来自江苏省苏州市的医用耗材企业爱舍伦（920050.BJ）在北交所首发上市，该公司首发价格 15.98元/股，发行市盈率14.99倍，开盘大涨205.88%，截至收盘涨175.59%，报收44.04元/股，总市值近 30亿元。 在港股市场，去年迎来了久违的IPO盛宴，上海则在盛宴中占据C位，是年内赴港上市企业数量最多的 城市。 这是今年苏州的首家上市企业，回首去年，A股116家企业首发上市，苏州以新增12家上市公司的数 量，超越北京、上海，首次位居全国各城市的年度IPO榜首。 ...

Group 1 - Aishalon is a company focused on the research, development, production, and sales of disposable medical consumables in the rehabilitation care and medical protection sectors [2] - The company emphasizes innovation and development, catering to the professional needs of healthcare workers and patients, and aims for technological innovation and industrial upgrades [2] - Aishalon has expanded its product line to include disinfection, household protection, and emergency protection products, while also providing ODM/OEM services for internationally recognized medical device brands [2] Group 2 - Aishalon operates multiple self-owned factories located in Jiangsu Province (Zhangjiagang and Yancheng), Anhui Province (Xuancheng), Thailand (Ayutthaya), and Morocco, with products exported to over 50 countries and regions including Europe, America, Japan, South Korea, the Middle East, and Africa [2] - Zhonglun Law Firm serves as the issuer's lawyer for Aishalon's public offering and listing project on the Beijing Stock Exchange, providing comprehensive and high-quality legal services throughout the issuance and listing process [2] - The project team includes partners Sun Yu and Qiao Wenjun, along with lawyer Wu Weiwei, and regional partner Cheng Chi, demonstrating a rigorous and professional service approach [2]

A股看苏州，港股看上海。 1月21日，来自江苏省苏州市的医用耗材企业爱舍伦（920050.BJ）在北交所首发上市，该公司首发价格 15.98元/股，发行市盈率14.99倍，开盘大涨205.88%，截至收盘涨175.59%，报收44.04元/股，总市值近 30亿元。 这是今年苏州的首家上市企业，回首去年，A股116家企业首发上市，苏州以新增12家上市公司的数 量，超越北京、上海，首次位居全国各城市的年度IPO榜首。 在港股市场，去年迎来了久违的IPO盛宴，上海则在盛宴中占据C位，是年内赴港上市企业数量最多的 城市。 苏州晋升A股IPO"第一城" 城市IPO数量，不仅是一把解读区域经济竞争力与未来发展潜力的钥匙，同时也衡量了各城市产业升级 成效、创新生态活力与营商环境质量，成为观测中国经济发展脉络的重要微观切片。 在A股市场，东方财富Choice数据显示：去年全年A股首发上市企业116家，相较2024年的100家，同比 增长了16%。 按省份划分，上述116家上市企业来自19个省份（包括直辖市），江苏、广东、浙江等3个省份依旧位列 A股IPO第一梯队，占全年IPO总量的58%。 其中，江苏以去年29家新增首发上市 ...

Group 1 - Aishalon Medical Technology Group Co., Ltd. has been listed on the Beijing Stock Exchange, marking it as the first new A-share listed company in Jiangsu Province for 2026 and the first in Suzhou's Xiangcheng District [1] - The company's stock price surged by 175.59% on its first trading day [1] - Aishalon specializes in the research, production, and sales of disposable medical consumables, focusing on rehabilitation care and surgical infection control [1] Group 2 - The company reported a revenue of 692 million yuan and a net profit of 80.71 million yuan for 2024, with projected revenue for 2025 expected to reach between 890 million and 940 million yuan, representing a year-on-year growth of 28.65% to 35.89% [1] - Aishalon holds 46 utility model patents, 10 design patents, 21 invention patents, and 2 copyrights, with 6 invention patents currently under review [1] - The company plans to use the funds raised from its public offering of 16.92 million shares at a price of 15.98 yuan per share to invest in the "Kaipule Public Health Medical Supplies Industrial Park Construction Project," which has a total investment of 670 million yuan [2]

（文章来源：证券时报网） 2022年度至2025年1-6月，爱舍伦主营业务收入分别为5.72亿元、5.72亿元、6.89亿元及4.36亿元，最近 三年收入复合增长率为9.73%，收入稳步增长。公司主营业务收入主要来源于境外销售。报告期各期， 公司境外销售收入分别为5.2亿元、5.39亿元、6.52亿元和4.21亿元，占当期主营业务收入比例分别为 90.99%、94.25%、94.71%和96.54%，境外销售收入占比较高，公司产品主要销往美国、欧洲、韩国等 国家和地区。 结合目前的订单情况、经营状况以及市场环境，爱舍伦预计2025年度营业收入约为8.90亿元至9.40亿 元，同比增长幅度约为28.65%至35.89%，主要系下游需求增加及公司产能扩大，公司业务规模扩大； 归属于母公司所有者的净利润约为8929.26万至9847.74万元，同比增长幅度约为10.63%—22.01%;归属于 母公司所有者的扣除非经常性损益后的净利润约为8610.78至9529.27万元，同比增长幅度约为19.37%至 32.11%。 通过此次成功发行及募投项目的陆续实施，爱舍伦将进一步提升现有产品产能，加大新型医用耗材研发 投入 ...

随着国亮新材上市在即，截至1月22日，北交所月内上市的新股将达到3只。 对比此前情况，北交所的新股发行是否出现提速迹象？ 北交所的上市审核、新股发行正在密集开展，一周之内就有3场上市委会议、2只新股上市，以及2只新 股申购。 1月21日，爱舍伦（920050.BJ）登录北交所，上市首日大涨175.59%，当日报收44.04元/股，换手率达到 78.23%。当天，美德乐（920119.BJ）开启申购，每股发行价为41.88元，市盈率为14.99倍。明日（1月 22日），国亮新材（920076.BJ）将登陆北交所。 审核端，据北交所官网，本周（1月19日至23日），该所将共计召开3场上市委审议会议，至此，北交所 月内将安排了8场上市委会议，并连续出现"一周三审"的情况。 如何看待近期北交所的发行审核节奏？北京南山投资创始人周运南告诉第一财经，北交所新股冻资规模 持续保持高位，并有望继续冲高，市场释放出赚钱效应，市场高度期待北交所的新股上市提速、高质量 扩容。另有分析认为，结合2025年上市审核情况，北交所IPO正呈现"加速跑"态势。 一周三审、2股上市、2股打新 本周上市的2只新股爱舍伦、国亮新材，IPO申请均在 ...

Group 1 - The core point of the news is the issuance of new stocks in the market, with a total of 8 companies raising a cumulative amount of 7.498 billion yuan so far this year, averaging 937 million yuan per company [1][2] - The newly issued stocks include 2 from the Shanghai main board, 1 from the Sci-Tech Innovation Board, and 5 from the Beijing Stock Exchange, with total fundraising amounts of 4.158 billion yuan, 1.561 billion yuan, and 1.779 billion yuan respectively [1] - The company with the highest fundraising amount is Zhenstone Co., Ltd., raising 2.919 billion yuan primarily for the construction of fiberglass product production bases and composite material production bases [1] Group 2 - The average initial issuance price of new stocks this year is 28.82 yuan, with the highest price being 92.18 yuan for Hengyun Chang, followed by Meidele and Nongda Technology at 41.88 yuan and 25.00 yuan respectively [2] - The geographical distribution of newly issued stocks shows a concentration in Zhejiang, Liaoning, and Jiangsu, with the highest fundraising amounts from Zhejiang, Guangdong, and Chongqing at 3.163 billion yuan, 1.561 billion yuan, and 1.240 billion yuan respectively [2] - The detailed list of newly issued stocks includes Zhenstone Co., Ltd. with 26,105.50 million shares at 11.18 yuan raising 2.919 billion yuan, and Hengyun Chang with 1,693.06 million shares at 92.18 yuan raising 1.561 billion yuan [2]

Market Overview - As of January 21, the Shanghai Composite Index closed at 4116.94 points, up by 3.29 points, with a growth rate of 0.08% [1] - The Shenzhen Component Index closed at 14255.13 points, increasing by 99.50 points, representing a growth rate of 0.70% [1] - The ChiNext Index closed at 3295.52 points, rising by 17.54 points, with a growth rate of 0.54% [1] High Turnover Stocks - A total of 80 A-shares had a turnover rate exceeding 20% on this day, with Aisheren reaching a turnover rate of over 50% [1] - The stock Aisheren had a closing price of 44.04 yuan, with a turnover rate of 78.23% and a significant increase of 175.59% [1] - Other notable stocks with high turnover rates include: - Nabai Chuan: Closing price 86.26 yuan, turnover rate 44.53%, increase of 9.87% [1] - Guangdian Electric: Closing price 6.09 yuan, turnover rate 44.40%, increase of 9.93% [1] - Jintaiyang: Closing price 39.13 yuan, turnover rate 44.16%, increase of 19.96% [1] Additional High Turnover Stocks - Other stocks with notable turnover rates include: - Blue Arrow Electronics: Closing price 36.75 yuan, turnover rate 43.18%, increase of 2.45% [1] - Sanbian Technology: Closing price 21.06 yuan, turnover rate 41.55%, decrease of 8.03% [1] - Hongbaoli: Closing price 9.59 yuan, turnover rate 39.79%, increase of 9.98% [1] - The stock with the highest turnover rate in the second list is Tai Li Technology, with a turnover rate of 28.52% and an increase of 6.32% [2] Summary of Notable Stocks - The stock with the highest turnover in the third list is Tian Di Online, with a turnover rate of 22.08% and an increase of 10.01% [3] - Other significant stocks include: - New Henghui: Closing price 85.76 yuan, turnover rate 22.04%, increase of 2.22% [3] - Jiangtian Chemical: Closing price 31.56 yuan, turnover rate 22.01%, increase of 4.12% [3]

Core Viewpoint - The medical device sector experienced a rise of 0.54% on January 21, with N Aisheren leading the gains, while the Shanghai Composite Index increased by 0.08% and the Shenzhen Component Index rose by 0.7% [1] Group 1: Stock Performance - N Aisheren (code: 920050) closed at 44.04, with a remarkable increase of 175.59% and a trading volume of 141,600 shares [1] - Tianzhihang (code: 688277) saw a rise of 12.38%, closing at 23.88 with a trading volume of 376,500 shares [1] - Xishan Technology (code: 688576) increased by 11.18%, closing at 76.80 with a trading volume of 34,000 shares [1] - Kangzhong Medical (code: 688607) rose by 10.91%, closing at 59.67 with a trading volume of 76,200 shares [1] - Shuoshi Biological (code: 6658889) increased by 9.74%, closing at 84.84 with a trading volume of 70,300 shares [1] Group 2: Capital Flow - The medical device sector saw a net inflow of 300 million yuan from institutional investors, while retail investors experienced a net outflow of 430 million yuan [2] - Major stocks like Sainuo Medical (code: 688108) had a net inflow of 69.18 million yuan from institutional investors, but a net outflow of 44.76 million yuan from retail investors [3] - LePu Medical (code: 300003) had a net inflow of 48.54 million yuan from institutional investors, with a slight net inflow of 0.52 million yuan from retail investors [3]